An observational study in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed. Per ClinicalTrials.gov, last updated 2014-09-04.
Sponsored by Boehringer Ingelheim · Observational
Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 1,464 is above the median of 96 across 1,057 observational studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Ambulatory patients with idiopathic parkinson's disease requiring therapy with Sifrol®
Exclusion Criteria:
Drug: Sifrol®
Change in Parkinson signs and symptoms by means of a 4-point rating scale
Time frame: up to 6 weeks
Occurrence of tremor (rest and postural) by means of a 4-point rating scale
Short Parkinson's Evaluation Scale (SPES)
Time frame: up to 6 weeks
Change in severity of kinetic tremor assessed by tremor spiral test
Time frame: up to 6 weeks
Occurrence of depression by means of a 4-point SPES rating scale
Time frame: up to 6 weeks
Change in severity of depression by means of an 8-point rating scale
Clinical Global Impression (CGI) rating scale
Time frame: up to 6 weeks
Self-Assessment of depression by patient by means of six different visual analogue scales (VAS)
VAS (10 cm)
Time frame: up to 6 weeks
Assessment of efficacy by investigator on a 5-point rating scale
Time frame: after 6 weeks
Number of patients with adverse drug reactions
Time frame: up to 6 weeks
Assessment of tolerability by investigator on a 5-point scale
Time frame: after 6 weeks
Assessment of tolerability by patient on a 5-point scale
Time frame: after 6 weeks
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim